Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

(S)-CR8 [1084893-56-0]

Research Use Only
AG-MR-C0004
AdipoGen Life Sciences
CAS Number1084893-56-0
Product group Chemicals
Estimated Purity>99% (NMR)
Molecular Weight431.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    (S)-CR8 [1084893-56-0]
  • Delivery Days Customer
    10
  • CAS Number
    1084893-56-0
  • Certification
    Research Use Only
  • Estimated Purity
    >99% (NMR)
  • Hazard Information
    Non-hazardous,Warning
  • Molecular Formula
    C24H29N7O
  • Molecular Weight
    431.5
  • Scientific Description
    Chemical. CAS: 1084893-56-0. Formula: C24H29N7O. MW: 431.5. Potent cyclin-dependent kinase (CDK) 1, 2, 5, and 9 inhibitor. Apoptosis inducer. Inhibits the proliferation of various cancer cell lines. Inhibits cysts formation in culture. Casein kinase 1 (CK1delta/epsilon) and Dyrk1A inhibitor. Down regulates expression of Mcl-1 and MYCN. Neuroprotective in experimental traumatic brain injury. Potential anti-inflammatory compound. Potential antidiabetic compound. - Potent cyclin-dependent kinase (CDK) 1, 2, 5, and 9 inhibitor [1, 2]. Apoptosis inducer [1, 3, 5]. Inhibits the proliferation of various cancer cell lines [1]. Inhibits cysts formation in culture [4]. Casein kinase 1 (CK1delta/epsilon) and Dyrk1A inhibitor [1]. Down regulates expression of Mcl-1 and MYCN. Neuroprotective in experimental traumatic brain injury. Potential anti-inflammatory compound. Potential antidiabetic compound.
  • SMILES
    CC[C@@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=C(C=C2)C2=NC=CC=C2)=N1
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases: K. Bettayeb, et al.; Oncogene 27, 5797 (2008)
  • Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1: N. Oumata, et al.; J. Med. Chem. 51, 5229 (2008)
  • CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells: K. Bettayeb, et al.; Genes Cancer 1, 369 (2010)
  • CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD: N.O. Bukanov, et al.; Cell Cycle 11, 4040 (2012)
  • CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. S.V. Kabadi, et al.; Neurotherapeutics 9, 405 (2012)
  • Inhibition of NF-kappaB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells: E. Cosimo, et al.; Clin. Cancer Res. 19, 2393 (2013)